Palantir shares rise 5% premarket as AI-fueled demand powers annual guidance raise
SAN RAMON, Calif. - CooperCompanies (NASDAQ:COO), a prominent medical device company with a market capitalization of $16.3 billion, announced the appointment of Barbara Carbone as an independent director to its Board, effective from May 1, 2025. According to InvestingPro data, the company maintains a GOOD financial health score, with particularly strong profitability metrics. Carbone, whose career spans nearly four decades, will also join the Audit Committee upon her board induction.
Carbone’s professional background is deeply rooted in audit and finance, having dedicated 38 years to KPMG LLP, with 24 years as an Audit Partner. Her tenure at KPMG included six years on the Partnership Audit Committee, three of which she served as Chairperson. She also led as the National Partner in Charge for Human Resources, focusing on performance management, compensation strategies, and training programs. After retiring from KPMG, Carbone continued to contribute her expertise on various boards, including TrueCar, Inc., Limoneira Company, and Bob’s Discount Furniture.
Bob Weiss, Chairman of the Board of CooperCompanies, expressed enthusiasm for Carbone’s joining, highlighting her "extensive financial and accounting expertise, leadership skills, and a great background in Human Resources." He anticipates her contributions will be valuable to the Board’s operations.
CooperCompanies operates through two primary business units, CooperVision and CooperSurgical. CooperVision is known for its role in the contact lens market, while CooperSurgical focuses on fertility and women’s healthcare. The company, which generated revenues of $3.9 billion in the last twelve months with a robust gross margin of 67%, employs over 16,000 people and has a product presence in more than 130 countries, impacting over fifty million lives annually. InvestingPro analysis indicates the company is currently trading below its Fair Value, suggesting potential upside opportunity. Discover detailed valuation metrics and 12+ additional exclusive ProTips with an InvestingPro subscription.
This strategic board appointment comes as CooperCompanies continues to expand its global presence and strengthen its governance with experienced leaders, maintaining steady revenue growth of 7.2% year-over-year. The addition of Carbone is expected to support the company’s commitment to its stakeholders and enhance its oversight capabilities, building on its strong financial position with a healthy current ratio of 1.99 and an impressive Altman Z-Score of 5.08, indicating solid financial stability.
The information for this report is based on a press release statement by CooperCompanies.
In other recent news, The Cooper Companies reported first-quarter fiscal year 2025 results, revealing a revenue of $965 million, which fell short of the anticipated $978 million. Despite the revenue miss, the company achieved an adjusted earnings per share of $0.92, slightly surpassing the consensus estimate of $0.91. Analysts from Stifel, Piper Sandler, and Jefferies have made adjustments to their price targets for Cooper Companies, with Stifel lowering its target to $105 while maintaining a Buy rating, Piper Sandler reducing it to $115 with an Overweight rating, and Jefferies adjusting it to $110 while still endorsing a Buy rating. The company’s management has maintained its full-year 2025 guidance, expecting organic growth in its CooperVision and CooperSurgical segments, despite challenges in the Asia-Pacific region and the fertility business.
Needham has maintained a Hold rating, noting that the company’s performance suggests a stronger second half of the fiscal year, with potential benefits from foreign exchange rates not yet factored into the guidance. Cooper Companies’ board of directors saw the re-election of seven directors at the annual meeting, and shareholders approved key proposals, including an amendment to the corporate charter. Additionally, KPMG LLP was ratified as the independent auditor for the fiscal year ending October 31, 2025. The company continues to focus on expanding its MyDay contact lenses and improving supply dynamics in the contact lens market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.